Anti-cancer drug discovery and development in Brazil: Targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds

Oncologist

Volumn 5, Issue 3, 2000, Pages 185-198

  Mans, Dennis R A ^a   Da Rocha, Adriana B ^a   Schwartsmann, Gilberto ^a,b  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Compound acquisition; Compound selection; Drug discover; Natural products; South America

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; BUSULFAN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; PLANT EXTRACT; PROCARBAZINE; TAXANE DERIVATIVE; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

ARTICLE; BRAZIL; CANCER CHEMOTHERAPY; CHEMICAL COMPOSITION; DRUG RESEARCH; HERBAL MEDICINE; HUMAN; MEDICINAL PLANT; NONHUMAN; PHYTOCHEMISTRY; PLANT; PRIORITY JOURNAL;

EID: 0033920537     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-3-185     Document Type: Article

References (124)

1. Yarbro JW. The scientific basis of cancer chemotherapy. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore: Williams & Wilkins, 1992:2-14.
2. Chabner BA. Anti-cancer drugs. (Chapter 18). In: DeVita VT Jr, Hellman S, Rosenberg AS, eds. Cancer: Principles and Practice, Fourth Edition. Philadelphia: Lippincott, 1991:325-417.
3. Jessup JM, McGinnis LS, Winchester DP et al. Clinical highlights from the National Cancer Database: 1996. CA Cancer J Clin 1996;46:185-187.
4. Fact sheet. Twelve major cancers. Scientific Am 1996;275:92-98.
5. Yarbro JW. The scientific basis of cancer chemotherapy (Chapter 1). In: Perry MC, ed. The Chemotherapy Source Book. Baltimore: Williams & Wilkins, 1992:2-14.
6. Sikora K, Advani S, Koroltchouk V et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 1999;10:385-390.
7. Harvey AL. Advances in Drug Discovery Techniques. Chicester: John Wiley & Sons, 1998.
8. Dolle RE. Comprehensive survey of chemical libraries yielding enzyme inhibitors, receptor agonists and antagonists, and other biologically active agents. Mol Divers 1997;2:223-236.
9. Hogan JC. Directed combinatorial chemistry. Nature 1996;384(suppl):17-19.
10. Nefzi A, Ostresh JM, Houghten RA. Combinatorial chemistry: from peptides and peptidomimetics to small organic heterocyclic compounds. Chem Rev 1997;97:449-472.
11. Cragg GM, Newmann DJ, Snader KM. Natural products in drug discovery and development. Nat Prod 1997;60:52-60.
12. Harvey AL, Bradley KN, Cochran AS et al. What can toxins tell us for drug discovery? Toxicon 1998;36:1635-1640.
13. Dolle RE, Nelson KH Jr. Comprehensive survey of combinatorial library synthesis: 1998. J Comb Chem 1999;4:235-282.
14. Harvey AL. Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol Sci 1999;20:196-198.
15. Farnsworth NR. The role of medicinal plants in drug development. In: Krogsgaard-Larsen P, Christensen SB, Kofod H, eds. Natural Products and Drug Development. London: Ballière, Tindall, and Cox, 1984:8-98.
16. Cox PA. The ethnobotanical approach to drug discovery: strengths and limitations. In: Chadwick DJ, Marsh J, eds. CIBA Foundation Symposium 185 - Ethnobotany and the Search for New Drugs. Chichester: John Wiley & Sons, 1994:25-41.
17. Samuelsson G. Drugs of Natural Origin. Stockholm: Swedish Pharmaceutical Press, 1992.
18. Farnsworth NR. The role of ethnopharmacology in drug development. In: Chadwick DJ, Marsh J, eds. CIBA Foundation Symposium 154 - Bioactive Compounds from Plants. Chichester: John Wiley & Sons, 1994:25-41.
19. Johnson IS, Armstrong JG, Gorman M et al. The Vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963;23:1390-1397.
20. DeVita VT Jr, Serpick AA, Carbone PO. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-895.
21. Stähelin H. Actvity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 1973;9:215-221.
22. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-1440.
23. Wani MC, Taylor HL, Wall ME et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
24. Wall ME, Wani MC, Cook CE et al. Plant anti-tumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-3890.
25. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
26. Bertino JR. Irinotecan for colorectal cancer. Semin Oncol 1997;24:S18-S23.
27. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. J Clin Oncol 1996;14:3056-3061.
28. Powell RG, Weisleder D, Smith CR Jr et al. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahydron Lett 1970;11:815-818.
29. Kantarjian HM, O'Brien S, Anderlini P et al. Treatment of myelogenous leukemia: current status and investigational options. Blood 1996;87:3069-3081.
30. Rehm S, Devor DE. Acute effects of 4-ipomeanol on experimental lung tumors with bronchiolar or alveolar cell features in Syrian hamsters or C3H/HeNCr mice. J Cancer Res Clin Oncol 1993;120:41-50.
31. Rowinsky EK, Noe DA, Ettinger DS et al. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res 1993;53:1794-1801.
32. Cragg G, Suffness M. Metabolism of plant-derived anti-cancer agents. Pharmacol Ther 1988;37:425-432.
33. Paoletti C, Le Pecq JB, Dat Xuong N et al. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium and 9-hydroxy-derivatives: preliminary clinical trials of 2-methyl-9-hydroxy-ellipticinium (NSC 264-137). Recent Res Cancer Res 1980;74:107-112.
34. Harmon AD, Weiss U, Silverton JV. The structure of rohutukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Maliaceae). Tetrahydron 1979;8:721-724.
35. Sedlacek HH, Czech J, Naik RG et al. Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996;9:1143-1168.
36. Losiewicz MD, Carlson BA, Kaur G et al. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589-595.
37. cdc kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol 1993;46:1831-1836.
38. Senderowicz AM, Headlee D, Stinson SF et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-2999.
39. Wright J, Blatner GL, Cheson BD. Clinical trials referral resource. Clinical trials of flavopiridol. Oncology (Huntingt) 1998;12:1023-1024.
40. Kaur G, Stetler-Stevenson M, Sebers S et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-1740.
41. Schultes RE. Amazonian ethnobotany and the search for new drugs. In: Chadwick DJ, Marsh J, eds. CIBA Foundation Symposium 154 - Ethnobotany and the search for new drugs. Chichester: John Wiley & Sons, 1994:106-115.
42. Balick MJ. Ethnobotany and the identification of therapeutic agents from the rainforest. In: Chadwick DJ, Marsh J, eds. CIBA Foundation Symposium 154 - Bioactive compounds from plants. Chichester: John Wiley & Sons, 1990:22-39.
43. Schweitzer J, Handley FG, Edwards J et al. Summary of the workshop on drug development, biologic diversity, and economic growth. J Natl Cancer Inst 1991;83:1294-1298.
44. Cragg GM, Newman DJ, Weiss RB. Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Semin Oncol 1997;24:156-163.
45. Hartwell JL. Types of anti-cancer agents isolated from plants. Cancer Treat Rep 1967;60:1031-1067.
46. Hartwell JL. Plants used against cancer. A survey. Lawrence, CA: Quarterman Publications, 1982.
47. Huxtable RJ. The pharmacology of extinction. J Ethnopharmacol 1992;37:1-11.
48. Han R. Recent progress in the study of anti-cancer drugs originating from plants and traditional medicines in China. Chin Med Sci J 1994;9:61-69.
49. Powis G. Anti-cancer drugs: antimetabolite metabolism and natural anti-cancer agents. Int Encycl Pharmacol Ther 1994;140:1-506.
50. Wong CK, Leung KN, Fung KP et al. Immunomodulatory and anti-tumour polysaccharides from medicinal plants. J Int Med Res 1994;22:299-312.
51. Moerman DE. Medicinal plants of Native America, vols 1 & 2. Ann Arbor: University of Michigan Museum of Anthropology Technical Reports, 1986.
52. Kapoor LD. CRC handbook of Ayurvedic medicinal plants. Boca Raton: CRC Press, 1990:317-343.
53. Tunon H, Bruhn JG. Drugs in ancient texts. Nature 1995;376:546.
54. Simões CMO, Mentz LA, Schenkel EP et al. Plantas da medicina popular no Rio Grande do Sul. Porto Alegre: Editora da Universidade/UFRGS, 1989.
55. Moreira F. Plantas que curam. São Paulo: Hemus Editora Limitada, 1996.
56. Komoda Y, Kishi T. Maytansinoids (Chapter 10). In: Cassady JM, Douros JD, eds. Anti-cancer Agents Based on Natural Product Models. New York: Academic Press, 1980:353-389.
57. Suffness M, Cordell GA. Antitumor alkaloids (Chapter I). In: Brossi A, ed. The Alkaloids. Chemistry and Pharmacology. Vol XXV. Orlando: Academic Press, 1985:142-155.
58. Peng SY, Norman J, Curtin G et al. Decreased mortality of Norman murine sarcoma in mice treated with the immunomodulator, acemannan. Mol Biother 1991;3:79-87.
59. Kaplan IW. Condylomata acuminata. New Orleans Med Surg J 1942;94:388-390.
60. Schall VT, Vasconcellos MC, Valent GU et al. Evaluation of the genotoxic activity and acute toxicity of Euphorbia splendens latex, a molluscicide for the control of schistosomiasis. Braz J Med Biol Res 1991;24:573-582.
61. Zamith HP, Paumgartten FJ, Speit G. Evaluation of the mutagenicity of the molluscicidal latex of Christ's Crown (Euphorbia milii var. hislopii) in mammalian cells in vitro and in vivo. Mutat Res 1996;368:15-20.
62. Wu TS, Lin YM, Haruna M et al. Antitumor agents, 119. Kansuiphorins A and B, two novel antileukemic diterpene esters from Euphorbia kansui. J Nat Prod 1991;54:823-829.
63. Fatope MO, Zeng L, Ohayaga JE et al. Selectively cytotoxic diterpenes from Euphorbia poisonii. J Med Chem 1996;39:1005-1008.
64. Paulini H, Popp R, Schimmer O et al. Isogravacridon-chlorine: a potent and direct acting frameshift mutagen from the roots of Ruta graveolens. Planta Med 1991;57:59-61.
65. Schimmer O, Kiefer J, Paulini H. Inhibitory effects of furocoumarins in Salmonella typhimurium TA98 on the mutagenicity of dictamnine and rutacridone, promutagens from Ruta graveolens. Mutagenesis 1991;6:501-506.
66. Morita H, Nakayama M, Kojima H et al. Structures and cytotoxic activity relationship of casearins, new clerodane diterpenes from Casearia sylvestris Sw. Chem Pharm Bull (Tokyo) 1991;39:693-697.
67. Itokawa H, Totsuka N, Morita H et al. New antitumor principles, casearins A-F, for Casearia sylvestris Sw. (Flacourticaceae). Chem Pharm Bull (Tokyo) 1990;38:3384-3388.
68. Wang LK, Johnson RK, Hecht SM. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 1993;6:813-818.
69. Yamashita Y, Fujii N, Nakano H. Identification of novel topoisomerase I inhibitors. Proc Am Assoc Cancer Res 1994;35:707.
70. Gopalakrishna R, Chen Z, Yoolee K et al. Chelerythrine and sanguinarine alkaloids induce membrane translocation and irreversible inactivation of protein kinase C by modifying thiol residues. Proc Am Assoc Cancer Res 1994;35:A3666.
71. Wolff J, Knipling L. Antimicrotubule properties of benzophenanthridine alkaloids. Biochemistry 1993;32:13334-13339.
72. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-291.
73. Antoun MD, Abramson D, Tyson RL et al. Potential antitumor agents. XVII. Physalin B and 25,26-epidihydrophysalin C from Witheringia coccoloboides. J Nat Prod 1981;44:579-585.
74. Chiang HC, Jaw SM, Chen PM. Inhibitory effects of physalin B and physalin F on various human leukemia cells in vitro. Anti-cancer Res 1992;12:1155-1162.
75. Chiang HC, Jaw SM, Chen CF et al. Antitumor agent, physalin F from Physalis angulata L. Anti-cancer Res 1992;12:837-843.
76. Pettit GR, Singh SB, Hamel E et al. Isolation and structure of the strong cell growth and tubulin inhibitor, combretastin A-4. Experientia 1989;45:209-211.
77. Pettit GR, Singh SB, Boyd MR et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem 1995;38:1666-1672.
78. El-Zayat AA, Degen D, Drabek S et al. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anti-cancer Drugs 1993;4:19-25.
79. Dorr RT, Dvorakova K, Snead K et al. Antitumor activity of combretastatin A-4 phosphate, a natural product tubulin inhibitor. Invest New Drugs 1996;14:131-137.
80. Dark GG, Hill SA, Prise VE at al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-1834.
81. Ley SV. Synthesis of antifeedants for insects: novel behaviour-modifying chemicals from plants. In: Chadwick DJ, Marsh J, eds. CIBA Foundation Symposium 154 - Bioactive Compounds From Plants. Chichester: John Wiley & Sons, 1990:80-98.
82. Kensil CR, Barrett C, Kushner N et al. Development of a genetically engineered vaccine against feline leukemia virus infection. J Am Vet Med Assoc 1991;199:1423-1427.
83. Gebara VC, Petricevich VL, Raw I et al. Effect of saponin from Quillaja saponaria (Molina) on antibody, tumour necrosis factor and interferon-gamma production. Biotechnol Appl Biochem 1995;22:31-37.
84. Robins DJ. Pyrrolizidine alkaloids. Nat Prod Rep 1995;12:413-418.
85. Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie 1995;50:83-98.
86. Kim H. Molecular toxicology of pyrrolizidine alkaloids. Diss Abstr Int [B] 1995;55:2684.
87. Miser JS, Smithson WA, Krivit W et al. Phase II trial of indicine N-oxide in relapsed pediatric solid tumors. A report from the children's cancer study group. Invest New Drugs 1991;9:339-342.
88. Miser JS, Smithson WA, Krivit W et al. Phase II trial of indicine N-oxide in relapsed acute leukemia of childhood. A report from the children's cancer study group. Am J Clin Oncol 1992;15:135-140.
89. Monks A, Scudiero D, Skehan P et al. Feasibility of a high-flux anti-cancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-766.
90. Boyd MR, Shoemaker RH, McLemore TL et al. New drug development. In: Roth JA, Ruckdescel JC, Weisenburger TH, eds. Thoracic Oncology. Philadelphia: Saunders, 1989:711-721.
91. Shoemaker RH, Monks A, Alley MC et al. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res 1988;276:265-286.
92. Paull KD, Shoemaker RH, Hodes L et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-1092.
93. Mongelli E, Desmarchelier C, Rodriguez-Talou J et al. In vitro antioxidant and cytotoxic activity of extracts of Baccharis cordifolia DC. J Ethnopharmacol 1997;58:157-163.
94. Fullas F, Hussain RA, Chai HB et al. Cytotoxic constituents of Baccharis gaudichaudiana. J Nat Prod 1994;57:801-807.
95. Anderson MM, O'Neill MJ, Phillipson JD et al. In vitro cytotoxicity of a series of quassinoids from Brucea javanica fruits against KB cells. Planta Med 1991;57:62-64.
96. Colson G, Rabault B, Lavelle F et al. Mode of action of the antitumor compound girodazole (RP 49532A. NSC 627434). Biochem Pharmacol 1992;43:1717-1723.
97. Satoh K, Ida Y, Sakagami H et al. Effect of antioxidants on radical intensity and cytotoxic activity of eugenol. Anti-cancer Res 1998;18:1549-1552.
98. Schwartsmann G, Mans DRA, Becker D et al. South-American Office for Anti-cancer Drug Development (SOAD): strategies to identify new anti-cancer drugs from natural products. Ann Oncol 1994;5 (suppl 8):181.
99. Stirpe F, Licastro F, Morini MC et al. Purification and partial characterization of a mitogenic lectin from the latex of Euphorbia marginata. Biochim Biophys Acta 1993;1158:33-39.
100. Dittrich H, Kutchan TM. Molecular cloning, expression, and induction of berberine bridge enzyme, an enzyme essential to the formation of benzophenanthridine alkaloids in the response of plants to pathogenic attack. Proc Natl Acad Sci USA 1991;88:9969-9973.
101. Kupchan SM, Smith RM. Maytolin, maytine, maytolidine, novel nicotinoyl sesquiterpene alkaloids from Maytenus serrata (Hochst., ex. A. Rich.). R. Wilcek. J Org Chem 1977;42:115-118.
102. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute. Maytansine, NSC 153858 - IND 11857. Annual report to the Food and Drug Administration. February 1984.
103. Grever MR, Chabner BA. Cancer drug discovery and development (Section 1, Chapter 18). In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Fourth Edition. Philiadelphia: Lippincott-Raven, 1997:328-339.
104. Kuo YH, King ML, Chen CF et al. Two new macrolide sesquiterpene pyridine alkaloids from Maytenus emarginata: emarginatine G and the cytotoxic emarginatine F. J Nat Prod 1994;57:263-269.
105. Shirota O, Morita H, Takeya K et al. Cytotoxic aromatic triterpenes from Maytenus ilicifolia and Maytenus chuchuhuasca. J Nat Prod 1994;57:1675-1681.
106. Kokoshka JM, Ireland CM, Barrows LR. Cell-based screen for identification of inhibitors of tubulin polymerization. J Nat Prod 1996;59:1179-1182.
107. Rao K, McBride TJ, Oleson JJ. Recognition and evaluation of lapachol as an antitumor agent. Cancer Res 1968;28:1952-1954.
108. Block JB, Serpick AA, Miller W et al. Early clinical studies with lapachol (NSC 11905). Cancer Chemother Rep 1974;(part 2.4):11-17.
109. Li CJ, Wang C, Pardee AB. Induction of apoptosis by betalapachone in human prostate cancer cells. Cancer Res 1995;55:3712-3715.
110. Mondin C, von Poser G, Mans DRA et al. Targeted plant collection as a rational means to acquire candidate anti-cancer compounds for screening. Ann Oncol 1998;9 (suppl 2):35.
111. th International Cancer Congress 1998;1481.
112. Takahashi I, Nakanishi S, Kobayashi E et al. Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. Biochem Biophys Res Commun 1989;165:1207-1212.
113. Grammas P, Moore P, Botchlet T et al. Cerebral microvessels in Alzheimer's have reduced protein kinase C activity. Neurobiol Aging 1995;16:563-569.
114. Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of an Hypericum preparation in 105 mildly depressed patients. J Geriatr Psychiatry Neuropharmacol 1994;(suppl 1):S9-S11.
115. Couldwell WT, Gopalakrishna R, Hinton DR et al. Hypericin: a potential antiglioma therapy. Neurosurgery 1994;35:705-710.
116. Zhang W, Hinton DR. Surnock AA et al. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery 1996;38:587-591.
117. Takahashi I, Nakanishi S, Kobayashi E et al. Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. Biochem Biophys Res Commun 1989;165:1207-1212.
118. Vukovic-Gacic B, Simic D. Identification of natural antimutagens with modulating effects on DNA repair. Basic Life Sci 1993;61:269-277.
119. Rocha L, Marston A, Potterat O et al. Antibacterial phloroglucinols and flavonoids from Hypericum brasiliense. Phytochemistry 1995;40:1447-1452.
120. Ferraz A, Mans DRA, Staats C et al. Antiproliferative activity of Hypericum species from Rio Grande do Sul. III Reunião da Sociedade Latino-Americana de Fitoquímica/IX Simpósio Latino-Americano Farmacobotânica, Gramado, RS. Anais Sociedade Latino-Americano de Fitoquímica 1999:P142.
121. Mans DRA, Ferraz A, von Poser G et al. Acquisition of candidate anti-cancer compounds through targeted plant collection. III Reunião da Sociedade Latino-Americana de Fitoquímica/IX Simpósio Latino-Americano Farmacobotânica, Gramado, RS. Anais Sociedade Latino-Americana de Fitoquímica 1999:P187.
122. Von Poser GL, Schripsema J, Ferraz AC et al. Anti-proliferative effects of substances isolated from South-Brazilian Hypericum species. Proc Am Assoc Cancer Res 2000;41:102.
123. Zhang D, Botos I, Gomis-Ruth FX et al. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (from d). Proc Natl Acad Sci USA 1994;91:8447-8451.
124. Chang CJ, Ashendel CL, Geahlen RL et al. Oncogene signal transduction inhibitors from medicinal plants. Anti-cancer Res 1995;15:1740-1741.